Capricor Therapeutics Faces Securities Class Action Over Deramiocel
Investors who purchased Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, are being urged to join a class action lawsuit. The litigation alleges the company misled shareholders by altering statistical analysis plans for its drug Deramiocel without prior FDA approval before resubmitting its application.
The legal action, filed by the DJS Law Group, centers on alleged violations of the Securities Exchange Act of 1934. According to the complaint, Capricor’s public statements were materially misleading because the company failed to secure regulatory consensus on changes to its clinical data analysis protocols. These undisclosed modifications to the Biologics License Application process for Deramiocel form the core of the allegations against the firm.
Shareholders seeking to act as lead plaintiff in the case must file their motions by September 28, 2026. While the DJS Law Group is actively soliciting participants to recover losses, legal representatives note that individual investors are not required to serve as lead plaintiffs to participate in any potential settlement. The firm specializes in corporate governance and securities litigation, representing a range of institutional investors and asset managers in similar recovery efforts.
Comments (0)
No comments yet. Be the first!